Daxor Corp (DXR) 6.25 $DXR
Daxor Corporation Announces Major Research Studies
Marketwired - Fri Jan 30, 7:31AM CST
Daxor Corporation (NYSE MKT: DXR) -- A study on 50 patients with severe sepsis published in the journal Critical Care Medicine, Volume 42, No. 12, December 2014, entitled Central Venous Pressure: Is It An Accurate Reflection of Intravascular Volume Status? analyzed whether central venous pressure is an accurate reflection of intravascular blood volume status. The authors of the study from the University of Hawaii, Drs. Catherine Lindsay McKnight, Mihae Yu, et al., utilizing the BVA-100 blood volume analyzer, found 17% of the patients who developed a normal or high central venous pressure can still be hypovolemic (low blood volume) and, therefore, would be under treated utilizing this common procedure.
DXR: 6.25 (+0.10)
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President
Marketwired - Thu Dec 18, 7:30AM CST
Daxor Corp (NYSE MKT: DXR) announced today that it has appointed Michael Feldschuh as Executive Vice President, to head business development and strategic initiatives for Daxor Corporation as part of the firm's effort to build its medical device business.
DXR: 6.25 (+0.10)
Daxor Corporation Announces a Major Study With the Mayo Clinic
Marketwired - Thu Dec 11, 7:56AM CST
Daxor Corporation, (NYSE MKT: DXR) announced its funding of a major study today for treating heart failure. The principal investigator for the study is Wayne Miller, M.D., PhD. Dr. Miller and his associates previously conducted a study on heart failure patients which was recently published in the Journal of the American College of Cardiology-Heart Failure. Heart failure is the leading cause of hospitalization for Medicare patients in the United States. Heart failure patients have a death rate of 35% to 40% in the first year after their initial hospitalization. Between 20% and 30% of hospitalized heart failure patients are readmitted to a hospital within 30 days. Starting in 2013, Medicare began charging hospitals a penalty for readmitting heart failure patients within 30 days. This study demonstrated that heart failure patients had serious blood volume derangements which were not uniform for individual patients. Fluid accumulation and blood volume expansion is one of the earliest changes in heart failure. Powerful diuretics are used to treat this condition. The over treatment of patients who do not have a blood volume expansion may result in a diminished blood volume and the precipitation of kidney failure. Some patients have unrecognized bleeding from the use of Anti-Coagulants. The majority of heart failure patients are treated without accurate knowledge of the patient's blood volume.
DXR: 6.25 (+0.10)
Daxor's board to pay USD0.03 per share dividend
M2 - Tue Nov 18, 5:55AM CST
The board of directors of Daxor (NYSE MKT
XR), a medical instrumentation company, declared on Monday its dividend of USD0.03 per share of its stock.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Payment of a Dividend
Marketwired - Mon Nov 17, 12:01PM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today.
DXR: 6.25 (+0.10)
Daxor Corporation declares $0.03 dividend
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:51AM CST
DXR: 6.25 (+0.10)
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating Blood Volume With Direct Measurement of Blood Volume
Marketwired - Mon Nov 03, 7:31AM CST
Daxor Corporation (NYSE MKT: DXR) -- The study (Brain-type natruretic peptide and right ventricular end-diastolic volume index measurements in imprecise estimates of circulating blood volume in critically ill subjects. J Trauma Acute Care Surg, Volume 75, Number 5) involved 81 subjects; 42% of the subjects had septic shock/severe sepsis. The mortality rate of this group was 17%. The conclusion of the study proved that right ventricular end-diastolic volume index (RVEDVI) and brain-type natriuretic peptide (BNP) measurements "did not correlate with blood volume status as determined by the BVA-100 Analyzer in critically ill surgical patients in whom pulmonary artery catheterization (PAC) insertion was used to guide treatment. These results suggest that RVEDVI and BNP, in common use clinically, are not precise indices of intravascular volume status, although these parameters may reflect cardiac preload". "The importance of this study is that clinicians must be cognizant of the limitations of currently available modalities that are being used in clinical decision making to optimize volume loading". The study further indicates that "directly measuring circulating blood volume (BV) may provide valuable insight into intravascular volume status, while at the same time furnishing a practical means to judiciously guide fluid management" and that "technologic innovations have made BV measurements in real time more feasible and useful with the development of the semi-automated, Food and Drug Administration-approved BVA-100 Blood Volume Analyzer" manufactured by the Daxor Corporation.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn Patients
Marketwired - Tue Oct 21, 8:31AM CDT
Dr. Joseph Feldschuh, President and CEO of the Daxor Corporation (NYSE MKT: DXR), announced an agreement with Virginia Commonwealth University (VCU) to do a 40 patient study on burn patients entitled "Measurement of Blood Volume Loss During Burn Surgery." The patients are treated and followed in a special intensive care unit for burn patients.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2014
Marketwire - Fri Aug 29, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2014. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-06302014.pdf.
DXR: 6.25 (+0.10)
Daxor to Explore Possible Partnership or Partial Sale of the Company
Marketwire - Thu Jun 19, 8:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Major Research Studies
Marketwired - Fri Jan 30, 7:31AM CST
Daxor Corporation (NYSE MKT: DXR) -- A study on 50 patients with severe sepsis published in the journal Critical Care Medicine, Volume 42, No. 12, December 2014, entitled Central Venous Pressure: Is It An Accurate Reflection of Intravascular Volume Status? analyzed whether central venous pressure is an accurate reflection of intravascular blood volume status. The authors of the study from the University of Hawaii, Drs. Catherine Lindsay McKnight, Mihae Yu, et al., utilizing the BVA-100 blood volume analyzer, found 17% of the patients who developed a normal or high central venous pressure can still be hypovolemic (low blood volume) and, therefore, would be under treated utilizing this common procedure.
DXR: 6.25 (+0.10)
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President
Marketwired - Thu Dec 18, 7:30AM CST
Daxor Corp (NYSE MKT: DXR) announced today that it has appointed Michael Feldschuh as Executive Vice President, to head business development and strategic initiatives for Daxor Corporation as part of the firm's effort to build its medical device business.
DXR: 6.25 (+0.10)
Daxor Corporation Announces a Major Study With the Mayo Clinic
Marketwired - Thu Dec 11, 7:56AM CST
Daxor Corporation, (NYSE MKT: DXR) announced its funding of a major study today for treating heart failure. The principal investigator for the study is Wayne Miller, M.D., PhD. Dr. Miller and his associates previously conducted a study on heart failure patients which was recently published in the Journal of the American College of Cardiology-Heart Failure. Heart failure is the leading cause of hospitalization for Medicare patients in the United States. Heart failure patients have a death rate of 35% to 40% in the first year after their initial hospitalization. Between 20% and 30% of hospitalized heart failure patients are readmitted to a hospital within 30 days. Starting in 2013, Medicare began charging hospitals a penalty for readmitting heart failure patients within 30 days. This study demonstrated that heart failure patients had serious blood volume derangements which were not uniform for individual patients. Fluid accumulation and blood volume expansion is one of the earliest changes in heart failure. Powerful diuretics are used to treat this condition. The over treatment of patients who do not have a blood volume expansion may result in a diminished blood volume and the precipitation of kidney failure. Some patients have unrecognized bleeding from the use of Anti-Coagulants. The majority of heart failure patients are treated without accurate knowledge of the patient's blood volume.
DXR: 6.25 (+0.10)
Daxor's board to pay USD0.03 per share dividend
M2 - Tue Nov 18, 5:55AM CST
The board of directors of Daxor (NYSE MKT
XR), a medical instrumentation company, declared on Monday its dividend of USD0.03 per share of its stock. DXR: 6.25 (+0.10)
Daxor Corporation Announces Payment of a Dividend
Marketwired - Mon Nov 17, 12:01PM CST
Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend today.
DXR: 6.25 (+0.10)
Daxor Corporation declares $0.03 dividend
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:51AM CST
DXR: 6.25 (+0.10)
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating Blood Volume With Direct Measurement of Blood Volume
Marketwired - Mon Nov 03, 7:31AM CST
Daxor Corporation (NYSE MKT: DXR) -- The study (Brain-type natruretic peptide and right ventricular end-diastolic volume index measurements in imprecise estimates of circulating blood volume in critically ill subjects. J Trauma Acute Care Surg, Volume 75, Number 5) involved 81 subjects; 42% of the subjects had septic shock/severe sepsis. The mortality rate of this group was 17%. The conclusion of the study proved that right ventricular end-diastolic volume index (RVEDVI) and brain-type natriuretic peptide (BNP) measurements "did not correlate with blood volume status as determined by the BVA-100 Analyzer in critically ill surgical patients in whom pulmonary artery catheterization (PAC) insertion was used to guide treatment. These results suggest that RVEDVI and BNP, in common use clinically, are not precise indices of intravascular volume status, although these parameters may reflect cardiac preload". "The importance of this study is that clinicians must be cognizant of the limitations of currently available modalities that are being used in clinical decision making to optimize volume loading". The study further indicates that "directly measuring circulating blood volume (BV) may provide valuable insight into intravascular volume status, while at the same time furnishing a practical means to judiciously guide fluid management" and that "technologic innovations have made BV measurements in real time more feasible and useful with the development of the semi-automated, Food and Drug Administration-approved BVA-100 Blood Volume Analyzer" manufactured by the Daxor Corporation.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn Patients
Marketwired - Tue Oct 21, 8:31AM CDT
Dr. Joseph Feldschuh, President and CEO of the Daxor Corporation (NYSE MKT: DXR), announced an agreement with Virginia Commonwealth University (VCU) to do a 40 patient study on burn patients entitled "Measurement of Blood Volume Loss During Burn Surgery." The patients are treated and followed in a special intensive care unit for burn patients.
DXR: 6.25 (+0.10)
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2014
Marketwire - Fri Aug 29, 7:30AM CDT
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2014. Copies of the form will be mailed to the Company's shareholders and are available on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-06302014.pdf.
DXR: 6.25 (+0.10)
Daxor to Explore Possible Partnership or Partial Sale of the Company
Marketwire - Thu Jun 19, 8:30AM CDT
Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
DXR: 6.25 (+0.10)
